Post-market Clinical Follow-up Study of Alcon TOTAL30® Contact Lenses (Lehfilcon A)
Launched by ALCON RESEARCH · May 7, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The Baseline visit is defined as the first office visit where an eye care professional provided an in-person office biomicroscopy exam to the subject, before or during which a TOTAL30 sphere or toric contact lens prescription was released. Baseline visit data will be collected retrospectively (chart review).
The Year 1 visit is defined as the visit that occurs 1 year (-2/+6 months) since the Baseline visit during which period the subject is wearing test lenses of the same design in both eyes, and a contact lens examination is performed. Year 1 data will be collected either retrospectively ...
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Wearers of lehfilcon A (sphere or toric) contact lenses of the same design in both eyes who have already begun use of the lens type and have purchased at least 3-month supply of lenses at the baseline timepoint;
- • Best corrected spectacle visual acuity (VA) 20/25 or better at baseline;
- • Healthy, non-diseased eyes;
- • Other protocol-specified inclusion criteria may apply.
- Key Exclusion Criteria, as determined or known by the Investigator:
- • Any ocular disease or condition that would contraindicate contact lens wear present at baseline;
- • The use of systemic or ocular medications that would contraindicate contact lens wear at baseline;
- • Participation in a contact lens or contact lens care product clinical trial during the period of the retrospective chart collection or during prospective study participation;
- • Other protocol-specified exclusion criteria may apply.
About Alcon Research
Alcon Research is a leading global company dedicated to advancing eye care through innovative research and development. As a subsidiary of Novartis, Alcon focuses on the development of cutting-edge products and therapies for vision correction and eye health, including surgical, pharmaceutical, and consumer eye care solutions. With a commitment to enhancing the quality of life for patients worldwide, Alcon Research conducts rigorous clinical trials to evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of care. Through collaboration with healthcare professionals and institutions, Alcon remains at the forefront of ophthalmic advancements, driving progress in the field of vision science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fort Worth, Texas, United States
Patients applied
Trial Officials
Clinical Trial Lead, Vision Care
Study Director
Alcon Research, LLC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported